Complementary Application of Milo Single-Cell Western Technology to Single-Cell Analysis of Cancer
November 3, 2020, 8:00 AM PST
Live Webinar
visit web site
Tumor cell-intrinsic mechanisms and complex interactions with the tumor microenvironment contribute to therapeutic failure via tumor evolution. It may be possible to overcome treatment resistance by developing a personalized approach based on a comprehensive analysis of tumors. We used single-cell analysis technologies to depict the tumor landscape of a single case of chemo-resistant metastatic, muscle-invasive urothelial bladder cancer (MIUBC) and found out that it was addicted to an HRAS mutation and that HRAS targeting treatment provoked upregulation of programmed death-ligand 1 (PD-L1) in surviving tumor cells. Based on the analysis, tipifarnib, a HRAS-targeting agent and then, atezolizumab, a PD-L1 inhibitor, was clinically applied; this resulted in a favorable response from the patient (Lee et al., 2020). In this study, we used the single-cell western blot technology (Milo) from Bio-techne to confirm the results from single-cell RNA sequencing. Since the targets of anti-cancer treatments are proteins, the expression and phosphorylation status of the proteins should be more predictive than the amount of mRNA. Comprehensive use of single-cell analysis technologies would expect accurate identification of personalized treatment targets for cancer patients. Speaker: Kyeung Min Joo, PhD Professor, Department of Anatomy and Cell Biology Sungkyunkwan University School of Medicine